Philippe De Wals1,2,3, Geneviève Deceuninck3, Brigitte Lefebvre4, Raymond Tsang5, Dennis Law5, Gaston De Serres2, Vladimir Gilca2, Rodica Gilca2, Nicole Boulianne2. 1. Department of Social and Preventive Medicine, Laval University, Quebec, Canada. 2. Division of Biological Risks and Occupational Health, Quebec National Public Health Institute ( Direction des risques biologiques et de la santé au travail, Institut national de santé publique du Québec ), Quebec, Canada. 3. Quebec University Hospital Research Centre, Quebec City, Canada. 4. Quebec Public Health Laboratory, Quebec National Public Health Institute (Laboratoire de santé publique du Québec), Sainte-Anne-de-Bellevue, Quebec, Canada. 5. National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Abstract
Background: Invasive meningococcal disease (IMD) incidence increased in Quebec, starting in 2003, and was caused by a serogroup B sequence type 269 clone. The Saguenay-Lac-Saint-Jean (SLSJ) region was particularly affected with a rate of 3.4 per 100000 person-years in 2006-2013. In May 2014, an immunization campaign was launched in SLSJ, using the 4-component protein-based meningococcal vaccine (MenB-4C). We aimed to evaluate the impact of the campaign 2 years after its initiation. Methods: Immunization registry data and serogroup B invasive meningococcal disease (B-IMD) cases notified to public health authorities and confirmed by culture or polymerase chain reaction from July 1996 to December 2016 were analyzed, including a multivariate Poisson regression model of incidence rates. Results: By the end of the campaign, 82% of the 59000 targeted SLSJ residents between 2 months and 20 years of age had been immunized. Following the initiation of the campaign, no B-IMD case occurred among vaccinees, whereas 2 cases were reported among unvaccinated adult SLSJ residents, and a third case in an unvaccinated child who had stayed in the region during the week prior to disease onset, in 2015. B-IMD incidence decreased in all other regions in the years 2015-2016 but sporadic cases continued to occur. A multivariate analysis showed a significant effect of the campaign in the SLSJ region (relative B-IMD risk: 0.22; P = .04). Conclusions: Results suggest a high level of protection provided by MenB-4C following mass vaccination at regional level. This, along with reassuring safety data, supports the current recommendations for MenB-4C use for controlling outbreaks caused by clones covered by the vaccine.
Background: Invasive meningococcal disease (IMD) incidence increased in Quebec, starting in 2003, and was caused by a serogroup B sequence type 269 clone. The Saguenay-Lac-Saint-Jean (SLSJ) region was particularly affected with a rate of 3.4 per 100000 person-years in 2006-2013. In May 2014, an immunization campaign was launched in SLSJ, using the 4-component protein-based meningococcal vaccine (MenB-4C). We aimed to evaluate the impact of the campaign 2 years after its initiation. Methods: Immunization registry data and serogroup B invasive meningococcal disease (B-IMD) cases notified to public health authorities and confirmed by culture or polymerase chain reaction from July 1996 to December 2016 were analyzed, including a multivariate Poisson regression model of incidence rates. Results: By the end of the campaign, 82% of the 59000 targeted SLSJ residents between 2 months and 20 years of age had been immunized. Following the initiation of the campaign, no B-IMD case occurred among vaccinees, whereas 2 cases were reported among unvaccinated adult SLSJ residents, and a third case in an unvaccinated child who had stayed in the region during the week prior to disease onset, in 2015. B-IMD incidence decreased in all other regions in the years 2015-2016 but sporadic cases continued to occur. A multivariate analysis showed a significant effect of the campaign in the SLSJ region (relative B-IMD risk: 0.22; P = .04). Conclusions: Results suggest a high level of protection provided by MenB-4C following mass vaccination at regional level. This, along with reassuring safety data, supports the current recommendations for MenB-4C use for controlling outbreaks caused by clones covered by the vaccine.
Authors: Rodolfo Villena; Marco Aurelio P Safadi; María Teresa Valenzuela; Juan P Torres; Adam Finn; Miguel O'Ryan Journal: Hum Vaccin Immunother Date: 2018-04-30 Impact factor: 3.452
Authors: Sami L Gottlieb; Francis Ndowa; Edward W Hook; Carolyn Deal; Laura Bachmann; Laith Abu-Raddad; Xiang-Sheng Chen; Ann Jerse; Nicola Low; Calman A MacLennan; Helen Petousis-Harris; Kate L Seib; Magnus Unemo; Leah Vincent; Birgitte K Giersing Journal: Vaccine Date: 2020-04-28 Impact factor: 3.641
Authors: Rodica Gilca; Philippe De Wals; Sheila M Nolan; Nicholas Kitchin; Joseph J Eiden; Qin Jiang; C Hal Jones; Kathrin U Jansen; Annaliesa S Anderson; Louise Pedneault Journal: mSphere Date: 2018-12-05 Impact factor: 4.389
Authors: Irene Rivero-Calle; Peter Francis Raguindin; Jose Gómez-Rial; Carmen Rodriguez-Tenreiro; Federico Martinón-Torres Journal: Infect Drug Resist Date: 2019-10-09 Impact factor: 4.003
Authors: Irene Rivero-Calle; Jose Gómez-Rial; Louis Bont; Bradford D Gessner; Melvin Kohn; Ron Dagan; Daniel C Payne; Laia Bruni; Andrew J Pollard; Adolfo García-Sastre; Denise L Faustman; Albert Osterhaus; Robb Butler; Francisco Giménez Sánchez; Francisco Álvarez; Myrsini Kaforou; Xabier Bello; Federico Martinón-Torres Journal: Hum Vaccin Immunother Date: 2020-08-05 Impact factor: 3.452